Issue 141 • April 2024

What’s next for AAV gene therapies in 2024?

Many high-profile adeno-associated virus (AAV) vector gene therapies for neuromuscular and blood disorders are anticipated in 2024.

Feature

Traceability technologies tighten supply chain fakery

Feature

Is HIV-TB coinfection treatment entering a new frontier?

Comment

AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay

Interview

Awareness key for digital therapeutics to realise full potential

Go to article: Home | What’s next for AAV gene therapies in 2024?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: Avenga Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Zenatek Company InsightGo to article: Simtra BioPharma SolutionsGo to article: In DepthGo to article: What’s Next for AAV Gene Therapies in 2024?Go to article: Traceability technologies tighten supply chain fakeryGo to article: Switching sales: Investigating the financial impacts of FDA’s priority vouchersGo to article: Is HIV-TB coinfection treatment entering a new frontier?Go to article: Patient organisations need to tackle transparency Go to article: AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay Go to article: Q&A: Increasing awareness around digital therapeutics key to realising full potentialGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue